Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients after allo-HSCT: A phase I trial.

Xiaoyu Zhu(University of Science and Technology of China), Liming Yang(Hunan Children's Hospital), Baolin Tang(University of Science and Technology of China), Guangyu Sun(University of Science and Technology of China), Tianzhong Pan(University of Science and Technology of China), Xingchi Chen(University of Science and Technology of China), Dongyao Wang(University of Science and Technology of China), Yongsheng Han(Anhui University of Traditional Chinese Medicine), Haicun Xie, Mei‐Juan Tu(University of California, Davis)
Journal of Clinical Oncology
May 28, 2025
Cited by 1


Related Papers